You are here: Industry Insights > Mylan

News List

Mylan and Upjohn, a division of Pfizer, to combine worldpharmanews
July 30, 2019
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business ...
Mylan, Upjohn Announce New Combined Business americanpharmaceuticalreview
July 30, 2019
Mylan and Pfizer announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
Mylan, Atomo Announce WHO Prequalification Approval for HIV Self Test americanpharmaceuticalreview
July 09, 2019
Mylan and medical device manufacturer Atomo Diagnostics announced the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO PQ).
Mylan investors favor expanding exec pay clawbacks. Will the company listen? fiercepharma
July 04, 2019
Mylan has faced investor pushback on its executive pay and governance for years and its 2019 shareholder's meeting was no exception.
Theravance, Mylan Expand YUPELRI® Development and Commercialization Agreement americanpharmaceuticalreview
June 20, 2019
Theravance Biopharma Ireland Limited and Mylan announced the expansion of the companies' current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories.
Theravance and Mylan expand agreement for nebulised revefenacin pharmaceutical-technology
June 19, 2019
Theravance Biopharma Ireland and Mylan have expanded their existing development and commercialisation agreement for nebulised revefenacin.
Health Canada approves Biocon and Mylan’s Ogivri for cancer treatment expressbpd
May 30, 2019
Ogivri, used for the treatment of HER2-Positive breast and gastric cancers, is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan’s joint portfolio approved in the market
Mylan investors are fed up with management—and for good reason, analysts say fiercepharma
May 12, 2019
The company's paying its chairman for not using its plane, for instance, and it's been shelling out to a company run by his brothers and son for decades.
TB Alliance, Mylan Announce Collaboration to Commercialize Pretomanid americanpharmaceuticalreview
April 19, 2019
Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).
Mylan and Hospira both recall injected drugs after particulate discovered in vials fiercepharma
March 20, 2019
Mylan and Hospira are both recalling injected medications because potentially dangerous particulate has been discovered in them.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page